Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nikoulina, S. E.
Right arrow Articles by Henry, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nikoulina, S. E.
Right arrow Articles by Henry, R. R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes 51:2190-2198, 2002
© 2002 by the American Diabetes Association, Inc.

Inhibition of Glycogen Synthase Kinase 3 Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle

Svetlana E. Nikoulina1,2, Theodore P. Ciaraldi1,2, Sunder Mudaliar1,2, Leslie Carter1,2, Kirk Johnson3, and Robert R. Henry1,2

1 Veterans Affairs San Diego Healthcare System, La Jolla, California
2 Department of Medicine, University of California, San Diego, La Jolla, California
3 Chiron Corporation, Emeryville, California


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Glycogen synthase kinase (GSK)-3 has been implicated in the regulation of multiple cellular physiological processes in skeletal muscle. Selective cell-permeable reversible inhibitors (INHs) of GSK-3 (CT98014 and CHIR98023 [Chiron, Emeryville, CA] and LiCl) were used to evaluate the role of GSK-3 in controlling glucose metabolism. Acute treatment (30 min) of cultured human skeletal muscle cells with either INH resulted in a dose-dependent activation of glycogen synthase (GS) with a maximally effective concentration of ~2 µmol/l. The maximal acute effect of either INH on GS (103 ± 25% stimulation over basal) was greater than the maximal insulin response (48 ± 9%, P < 0.05 vs. INH); LiCl was as effective as insulin. The GSK-3 inhibitor effect, like that of insulin, was on the activation state (fractional velocity [FV]) of GS. Cotreatment of muscle cells with submaximal doses of INH and insulin resulted in an additive effect on GS FV (103 ± 10% stimulation, P < 0.05 vs. either agent alone). Glucose incorporation into glycogen was also acutely stimulated by INH. While prolonged (6–24 h) insulin exposure led to desensitization of GS, INH continued to activate GS FV for at least 24 h. Insulin and LiCl acutely activated glucose uptake, whereas INH stimulation of glucose uptake required more prolonged exposure, starting at 6 h and continuing to 24 h. Chronic (4-day) treatment with INH increased both basal (154 ± 32% of control) and insulin-stimulated (219 ± 74%) glucose uptake. Upregulation of uptake activity occurred without any change in total cellular GLUT1 or GLUT4 protein content. Yet the same chronic treatment resulted in a 65 ± 6% decrease in GSK-3 protein and a parallel decrease (61 ± 11%) in GSK-3 total activity. Together with the INH-induced increase in insulin-stimulated glucose uptake, there was an ~3.5-fold increase (P < 0.05) in insulin receptor substrate (IRS)-1 protein abundance. Despite upregulation of IRS-1, maximal insulin stimulation of Akt phosphorylation was unaltered by INH treatment. The results suggest that selective inhibition of GSK-3 has an impact on both GS and glucose uptake, including effects on insulin action, using mechanisms that differ from and are additive to those of insulin.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Glycogen synthase kinase (GSK)-3 is a serine/threonine kinase originally discovered because of its ability to phosphorylate and inhibit glycogen synthase (GS) (1). Human GSK-3 exists as two isoforms, {alpha} and ß, encoded by two distinct genes, located on chromosomes 19q13.1-2 and 3q13.3-q21, respectively (2). GSK-3 is constitutively active in resting cells and is inhibited by several hormones such as insulin, endothelial growth factor, and platelet-derived growth factor. Insulin has been demonstrated to cause inactivation of GSK-3, both in vivo (3,4) and in several cell types (5–7). The mechanism of inactivation is associated with phosphorylation of the specific serine residues Ser21 and Ser9 in GSK-3 isoforms {alpha} and ß, respectively. Insulin deactivation of GSK-3 is phosphatidylinositol (PI) 3-kinase-dependent and probably occurs through protein kinase B/Akt (8,9), properties shared with insulin stimulation of GS.

GS activity is regulated by allosteric and covalent (phosphorylation/dephosphorylation) mechanisms (10–12). Whereas a number of kinases and phosphatases can act on GS, GSK-3 plays an important role (13–15). GSK-3 phosphorylates GS on three specific residues. This phosphorylation causes deactivation of GS and decreases its affinity to allosteric activation by glucose-6-phosphate. In addition, it has been reported that GSK-3 can also phosphorylate insulin receptor substrate (IRS)-1, a key early molecule in insulin-signaling cascades (16), suggesting the potential for involvement of GSK-3 in multiple stages of insulin action.

Lithium ion (Li) has been found to cause relatively specific inhibition of GSK-3 (15,17) and has been reported to have insulin-like effects on glucose metabolism, including increases in glucose uptake, activation of GS activity, and stimulation of glycogen synthesis in skin, muscle, and fat cells. However, Li can also inhibit myo-inositol-1-monophosphatase (18), 1,6 bisphosphatase, and other enzymes involved in regulation of glucose metabolism (19–21). Several other agents have also been reported to inhibit GSK-3 activity: Ro 31-8220, valproic acid, iodotubercidin, staurosporin, sangivemycin, and hymenialdisine (22). Like lithium, some of these inhibitors have been reported to exhibit antidiabetic effects (valproate) or to promote glycogen formation (iodotubercidin). However, these agents are not specific for GSK-3 inhibition and also inhibit other protein kinases involved in insulin signal transduction and/or glucose metabolism. Consequently, it has been difficult to confidently ascribe the insulin-like effects of these agents to GSK-3 inhibition alone.

Several recent observations suggest an important role for GSK-3 in the regulation of GS and possible involvement in the development of insulin resistance in type 2 diabetes. Overexpression of GSK-3 in 293 cells and 3T3-L1 adipocytes results in decreased GS affinity to glucose-6-phosphate as well as impaired insulin-stimulated IRS-1 phosphorylation (15,16). In addition, GSK-3 expression is elevated in skeletal muscle of type 2 diabetic subjects and is inversely related to whole-body insulin action (22). However, the physiological role of GSK-3 in insulin-sensitive tissues, such as skeletal muscle and especially its role in regulation of glucose metabolism, remains to be determined.

The current experiments used novel, potent, and selective inhibitors of GSK-3 to study the regulation of glucose metabolism and insulin action in the major insulin target tissue—skeletal muscle. These studies were performed in cultured human skeletal muscle cells, a system that closely reflects the in vivo metabolic behavior of skeletal muscle, including impaired insulin activation of GS (23–25).


   RESEARCH DESIGN AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Materials.
UDP-[14C]glucose, D-[U-14C]glucose, L-[14C]glucose, and [3H]-2-deoxyglucose were obtained from DuPont NEN (Boston, MA). [{gamma}-32P]ATP was purchased from ICN Pharmaceuticals (Costa Mesa, CA). Horseradish-conjugated anti-rabbit and anti-mouse IgG was obtained from Amersham (Arlington Heights, IL). SuperSignal Chemiluminescent Substrate was obtained from Pierce (Rockford, IL). BSA (Fraction V) and glucose-6-phosphate were purchased from Boehringer Mannheim (Indianapolis, IN). Protein assay reagents and electrophoresis chemicals were purchased from BioRad Laboratories (Hercules, CA). Glycogen, 2-deoxyglucose, pepstatin, leupeptin, phenylmethylsulfonyl fluoride (PMSF), and other reagents and chemicals were purchased from Sigma (St. Louis, MO). Anti-GSK-3/Shaggy protein kinase family (51/46-kDa) mouse monoclonal IgG, purified GSK-3{alpha} and -ß from rabbit skeletal muscle, and anti-rat COOH-terminal IRS-1 rabbit polyclonal IgG were purchased from Upstate Biotechnology (Lake Placid, NY). Akt antibody, which detects total Akt1, Akt2, and Akt3 isoforms, was obtained from Cell Signaling Technologies (Beverly, MA). The antibody against the S473 phosphorylated form of Akt was purchased from New England Biolabs (Beverly, MA). Antibodies against GLUT1 (polyclonal) and GLUT4 were obtained from Biogenesis (Kingston, NH). An affinity-purified chicken polyclonal antibody against GS was a gift from Dr. J.C. Lawrence, Jr. (University of Virginia, Charlottesville, VA). GSK-3 inhibitors CHIR 98014 and CHIR 98023 were obtained from Chiron (Emeryville, CA) and have been described previously (26). They inhibit GSK-3{alpha} and -ß in vitro with Ki = 16 nmol/l (98014) and Ki = 4 nmol/l (98023). Ki values are >=10 µmol/l for more than 20 other kinases, including cdc2, Akt, erk, PI 3-kinase, rsk, and InsRTK (26). A structurally related and inactive analog (IA) (Ki against GSK-3 >=1 µmol/l) was also used. Inhibitors (INHs) were diluted in DMSO to obtain a 10 mmol/l concentration (stock). Before being added to the cell cultures, the stock solution was mixed with serum-free media to obtain concentrations ranging from 0.5 to 5.0 µmol/l. In most experiments, the final concentration of DMSO (vehicle) in culture media was <0.0005%. This concentration of DMSO was tested in multiple experiments (n = 20) and did affect glucose metabolism in human skeletal muscle cultures.

Human skeletal muscle cell culture.
Skeletal muscle cell cultures were established from muscle tissue obtained by needle biopsy samples of the vastus lateralis. Muscle biopsy samples were obtained from 47 nondiabetic and type 2 diabetic patients. All subjects underwent a 2-h 75-g oral glucose tolerance test. Normal glucose tolerance was defined as a fasting glucose level <7.0 mmol/l and 2-h glucose level <7.8 mmol/l (27). The experimental protocol was approved by the Committee on Human Investigation of the University of California, San Diego. Informed written consent was obtained from all subjects after explanation of the protocol.

The method of culturing skeletal muscle cells from biopsy samples has been described in detail in several publications (24,25). Satellite cells were obtained by trypsin digestion of muscle biopsy material. Cells were propagated in culture by modifications of the methods described by Blau and Webster (28) and Sarabia et al. (29). When cells attained ~80% confluency, they were transferred to differentiation media. Differentiation into multinucleated myotubes was complete within 4 days. Media were changed every 48 h. When cells were treated chronically for 4 days, media with fresh agents were changed every other day. Acutely, cells were treated with the selective GSK-3 inhibitor CHIR 98024 or its IA in serum-free media for 30 min or as indicated and, in some cases, together with insulin (33 nmol/l) at the completion of the differentiation period.

GS activity.
GS activity was measured as described in detail previously (25,30). Cells from six-well plates were washed with PBS and scraped into 0.3 ml of extraction buffer (50 mmol/l HEPES, 10 mmol/l EDTA, 100 mmol/l NaF, 5 mmol/l dithiothreitol [DTT], 1 µmol/l leupeptin, 1 µmol/l pepstatin, and 200 µmol/l PMSF, pH 7.5). Protein concentration was determined by the Bradford method (31) with BSA as a standard. GS activity was determined at a physiological concentration of substrate (0.3 mmol/l UDP glucose) and expressed in nanomoles of UDP glucose incorporated into glycogen per minute per milligram of total protein and as fractional velocity (FV) (the ratio of activity assayed at 0.1 mmol/l glucose-6-phosphate divided by the activity at 10 mmol/l glucose-6-phosphate). This is believed to be an indicator of changes in the phosphorylation state of GS in response to insulin (12).

Glycogen synthesis.
Glycogen synthesis was determined in differentiated myotubes as D-[14C]glucose incorporation into glycogen during a 1-h incubation at 37°C (24). After incubation, cells were rinsed four times with PBS at 4°C and solubilized with 1N NaOH at 55°C for 1 h. An aliquot (100 µl) of the lysate was removed for protein analysis. The final glycogen pellets were resuspended in 0.5 ml H2O, mixed with scintillation fluid, and radioactivity determined by liquid scintillation counting. Absolute results are expressed as nanomoles glucose converted to glycogen per milligram protein per hour.

Assay of GSK-3 activity.
Total GSK-3 ({alpha} and ß) activity was measured in the homogenates against a peptide substrate (RRAAEELDSRAGpSPQL) derived from the e-subunit of eIF2-(SP). This peptide and control peptide [where the Ser(P) is replaced by Ala] were obtained from Chiron. After treatment, cells were rapidly washed with PBS at 4°C and then lysed in buffer containing 20 mmol/l Tris-HCl, 145 mmol/l NaCl, 10% glycerol, 5 mmol/l EDTA, 1% Triton X-100, 0.5% NP-40, 200 µmol/l sodium orthovanadate, 200 µmol/l PMSF, 1 µmol/l leupeptin, 1 µmol/l pepstatin, and 10 mg/ml aprotinin, pH 7.5. Kinase assays were performed on the cell homogenates in reaction mixtures that included 3 mg/ml peptide (substrate or control), 110 µmol/l [{gamma}-32P]ATP, 16 mmol/l magnesium chloride, 0.1 mg/ml BSA, 1 mmol/l DTT, and 20 mmol/l Tris, pH 7.4. Reactions were stopped by spotting 0.03-ml aliquots on Whatmann P81 paper squares and immediately transferring to cold 100 mmol/l phosphoric acid. Squares were washed three times with 100 mmol/l phosphoric acid and once with acetone and counted in a liquid scintillation counter. 32Pi incorporation into the negative control peptide was subtracted from values obtained using substrate peptide. GSK-3 activity was expressed as nCi of 32Pi incorporated into phosphopeptide per 30 min by 1 mg protein, measured by the Bradford assay (31).

Glucose uptake assay.
Glucose uptake measurements were performed as described previously (32). Serum-free media were added to the cells together with insulin (0–33 nmol/l), and the cells incubated for 120 min in a 5% CO2 incubator before washing, uptake assay, and solubilization. An aliquot of the suspension was removed for protein analysis using the Bradford method. The uptake of L-glucose was used to correct each sample for the contribution of diffusion. This procedure measures both the transport and phosphorylation of glucose. Control studies indicate that transport was the rate-limiting process under the assay conditions used.

Immunoblotting.
On the day of the experiment, control and insulin- or INH-treated cells were washed three times with ice-cold PBS and homogenized in a buffer containing 20 mmol/l Tris-HCl (pH 7.5), 1.5 mmol/l EGTA, 1 mmol/l EDTA, 10 mmol/l NaF, 1 mmol/l DTT, 0.5 mmol/l sodium orthovanadate, 10 µg/ml aprotinin, 20 µ g/ml leupeptin, 0.2 mmol/l PMSF, and 0.5% Triton X-100. The levels of GSK-3 isoforms ({alpha} and ß, Shaggy protein kinase family) were determined by Western blotting using monoclonal antibodies raised against a peptide with a common sequence for {alpha} and ß GSK-3 isoforms. Partially purified rabbit GSK-3{alpha} and/or GSK-3ß were included on each gel as internal standards. Other antibodies are described in RESEARCH DESIGN AND METHODS. Western blotting was performed by the method of Burnette (33). After SDS-PAGE (7.5 or 10%), proteins were transferred to nitrocellulose membranes. Nonspecific binding was reduced by incubation in a blocking solution containing Tris-buffered saline, 3% nonfat dry milk, and 0.05% Tween-20. Anti-mouse or anti-rabbit IgG conjugated with horseradish peroxidase was used as a secondary antibody. Proteins were visualized using the SuperSignal Chemiluminescent Substrate kit and exposed to specific supersensitive autoradiograph film (Hyperfilm; Amersham). Multiple exposures were performed to verify linearity of the images. The intensity of the bands was quantified by scanning densitometry using NIH Image software, and results were expressed in integrated optical density units per 0.01 mg total protein (arbitrary units).

Statistical analysis.
Statistical significance was evaluated with the Student’s t test. Paired analysis was used to determine the effect of the inhibitors in the same culture. All data and calculated results are expressed as the average ± SE. Significance was accepted at the P < 0.05 level.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Acute activation of GS by GSK-3 inhibitors.
Figure 1 presents the structures of the GSK-3 inhibitor compounds used in the current study. Confirmation of GSK-3 inhibition is presented in Fig. 1B. Direct addition of CHIR 98023 to the GSK-3 assay reduced enzyme activity by 72 ± 7% (P < 0.0005), whereas a structurally related inactive compound (IA) had no effect (1 ± 17% inhibition). Detailed dose-response curves performed with purified kinases revealed inhibitory potencies greater than those seen with whole-cell extracts (26).



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 1. GSK-3 inhibitory compounds. A: Structures of inhibitors studied. B: Effect of inhibitor (CHIR 98023) and IA on GSK-3 activity. Compounds (2 µmol/l) were added directly to GSK-3 assay before determination of enzyme activity. Results are average ± SE for assays performed on extracts prepared from cells of multiple individuals; n = 10 for CHIR 98023, and n = 5 for IA. *P < 0.0005 vs. control.

 
To determine whether specific inhibition of GSK-3 acutely controls GS activation in skeletal muscle, we used cell-permeable inhibitors of GSK-3—CHIR 98014 and CHIR 98023 (Chiron) (26), collectively referred to as INH and LiCl. Both INHs acutely activated GS FV in a dose-dependent manner with a similar concentration-response profile (CHIR 98023 shown in Fig. 2A). Maximal effects were observed at 1–2 µmol/l for both INHs. This effect was on the activation state (FV) of the enzyme because maximal GS activity was unaltered.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 2. Acute effects of insulin and GSK-3 inhibitors on GS FV in human skeletal muscle cells. A: Dose response. Human skeletal muscle cell cultures were incubated for 30 min with a range of concentrations of CHIR 98023 in fusion media at 37°C. Results are means ± SE, determined in three to five cell cultures obtained from nondiabetic subjects. GS activity is expressed as FV (GS FV), as described in RESEARCH DESIGN AND METHODS. B: Comparison of effects of agents in muscle cells from diabetic and nondiabetic subjects. Cell cultures were incubated for 30 min in serum-free media ({alpha}-MEM) containing 33 nmol/l insulin, 2.5 µ mol/l CHIR 98023 or IA, or 20 mmol/l LiCl. Results are means ± SE obtained from cell cultures of nondiabetic (n = 5–10) and type 2 diabetic (n = 5–10) subjects. C: Insulin and CHIR 98023 have additive effects on GS FV in human muscle cells. GS FV was determined in cells of seven subjects (three nondiabetic patients and four type 2 diabetic patients) after 30 min of treatment with 2.5 µmol/l CHIR 98023 alone (INH), insulin at a low concentration (IL) (1.7 nmol/l) or high concentration (IH) (33 nmol/l) alone, or a combination with 2.5 µmol/l CHIR 98023 (INH + I). Results are averages ± SE. *P < 0.05 vs. paired control; {dagger}P < 0.05 vs. paired insulin-treated value for same individual.

 
The effects of the inhibitors were compared with the maximal effects of insulin and LiCl (20 mmol/l). Stimulatory actions of the INHs were greater than the maximal insulin or LiCl effects (Fig. 2B). The structurally related compound that is inactive (IC50 100x >98014 or 98023) against GSK-3 (IA) had no effect on GS activity. Whereas values for GS FV (both basal and insulin-stimulated) in type 2 diabetic subjects were lower (P < 0.05) than those in the nondiabetic subjects, in agreement with earlier results (25), the relative effects of the INHs were similar in muscle cell cultures from nondiabetic and type 2 diabetic subjects (Fig. 2B). Because the absence or presence of diabetes did not influence the relative effects of INH treatment, data in the two subject groups were combined, although cells from each subject were assayed individually.

Possible interactions between GSK-3 inhibition and insulin action on GS were investigated by treating cells simultaneously with insulin and CHIR 98023. Cotreatment with submaximal concentrations of CHIR 98023 and insulin (10 nmol/l) had a synergistic effect on the GS activation state (Fig. 2C). Maximal insulin action was also augmented by CHIR 98023. CHIR 98023 addition after preincubation with a maximal insulin dose resulted in an amplification of the insulin effect on GS FV (data not shown) without altering total GS activity.

Kinetics of GS activation.
Differences were observed between the time course of GS activation by insulin and GSK-3 inhibitors. Insulin rapidly activated GS FV (Fig. 3). Stimulation increased for up to 2 h, followed by a return to near-basal activity after 24 h of treatment (Fig. 3). Chronically insulin-treated cells were also desensitized to subsequent acute insulin exposure (not shown). Similarly, LiCl also rapidly increased GS FV (30 min), but no effect was seen after prolonged exposure (Fig. 3). A biphasic effect of CHIR 98023 on GS FV was observed. There was rapid activation (0.5–2 h) of a magnitude greater than or equal to that of insulin or LiCl, which continued to increase until 24 h of treatment and was sustained for 96 h. The maximal activated GS FV, approximately fivefold that of control activity, could not be stimulated further by addition of acute insulin (not shown).



View larger version (17K):
[in this window]
[in a new window]
  		FIG. 3. Time course of GS activation by CHIR 98023 (2 µmol/l), insulin (33 nmol/l), or LiCl (20 mmol/l) in human skeletal muscle cultures (n = 4; 2 nondiabetic patients, 2 diabetic patients). Results are averages ± SE.

 
Effect of GSK-3 inhibition on glucose uptake.
GSK-3 has been proposed to play a role in insulin-regulated glucose uptake (34). Acute (2-h) exposure of muscle cells to a dose of CHIR 98023 that maximally activated GS FV resulted in an insignificant increase in glucose uptake (Fig. 4A) compared with the ~80% stimulation in response to insulin. Interestingly, similar to insulin, LiCl acutely stimulated glucose uptake (78 ± 16% increase, P < 0.05). As was the case for GS FV, prolonged exposure to insulin (24 h) or LiCl (96 h) led to a desensitization of glucose uptake, with both a return toward basal activity (Fig. 4A) and a failure to respond to subsequent acute insulin exposure (not shown). In contrast, INHs increased glucose uptake significantly at 6–24 h after CHIR 98023 treatment (284 ± 23%). Moreover, the increase was sustained for up to 96 h of treatment (Fig. 4A). A similar response was seen with CHIR 98014 (Fig. 4B). The inactive compound had no effect on glucose uptake after either acute or prolonged (Fig. 4B) treatment. Although cells chronically treated with insulin did not respond to subsequent acute insulin treatment (not shown), INH-treated cells displayed a further response to insulin (Fig. 4B). Insulin-stimulated uptake after INH treatment was approximately double that seen in control cells, whereas it was normal in LiCl-treated cells. Thus, sustained exposure to CHIR 98023 and CHIR 98014 resulted in upregulation of both basal and insulin-stimulated glucose uptake in skeletal muscle cells.



View larger version (28K):
[in this window]
[in a new window]
  		FIG. 4. Effect of GSK-3 inhibitors on basal and insulin-stimulated glucose uptake in human muscle cells. A: Time course of glucose uptake activation in human muscle cells by CHIR 98023 (2 µmol/l), insulin (33 nmol/l), or LiCl (20 mmol/l). Results are averages ± SE, normalized against glucose uptake in untreated control cells from the same individual (n = 4). B: Muscle cells from nondiabetic (n = 5) and type 2 diabetic (n = 4) subjects were treated for 4 days with CHIR 98023 (2.5 µmol/l), CHIR 98014 (2.5 µ mol/l), inactive compound (IA, 2.5 µmol/l), or LiCl (20 mmol/l), as described in detail in RESEARCH DESIGN AND METHODS. After chronic treatment, half of the cell cultures were washed with fresh media and incubated with 33 nmol/l insulin for 2 h. Results are averages ± SE, normalized against the control and basal value for each individual. *P < 0.05 vs. untreated paired control; {dagger}P < 0.05 vs. paired basal.

 
Regulation of glycogen formation.
The effects of GSK-3 inhibitors on the major fate of glucose in skeletal muscle—storage in glycogen—were also evaluated. Insulin and INHs acutely stimulated glucose incorporation into glycogen, whereas the inactive analog had no effect (Fig. 5). Similar results were observed in cultured liver cells using other selective inhibitors of GSK-3 (35). The responses to insulin and INHs were comparable. The combination of insulin and INHs tended (P < 0.1) to stimulate glycogen formation greater than that seen with either agent alone, as might be expected from the effect of insulin on glucose uptake (Fig. 4A) combined with maximal GS activation due to INHs.



View larger version (19K):
[in this window]
[in a new window]
  		FIG. 5. Regulation of glucose incorporation into glycogen in human muscle cells. Cells were acutely treated during the 1-h assay of 14C-glucose incorporation into glycogen with 2 µmol/l CHIR 98014 (INH) or IA, or LiCl (20 mmol/l). Results are averages ± SE; n = 4. *P < 0.05 vs. no addition.

 
Effect of GSK-3 inhibitors on protein expression.
Although the acute effects of INHs and LiCl on GS could be attributed to inhibition of GSK-3 activity, the temporally biphasic nature of the effect of CHIR 98023 on GS FV and glucose uptake suggests that additional mechanisms could be involved. Chronic (4-day) exposure of muscle cells to INHs resulted in a dose-dependent decrease (65%, P < 0.05) in the expression of GSK-3 protein (Fig. 6A). Both the {alpha} and ß isoforms were reduced (Fig. 5B) by 68 and 45%, respectively, after treatment with 2 µmol/l CHIR 98023. Neither the inactive compound nor LiCl had any effect. Under the same conditions, total GSK-3 activity was reduced by 61 ± 11% (P < 0.05). The decrease in enzyme activity is truly reflective of the decrease in GSK-3 protein and not a residual inhibitory effect of INH because cells were extensively washed before extraction and extracts were diluted during the assay, removing the effect of the inhibitors as might be expected, since the nature of the inhibition is ATP competitive and reversible (26). The results indicated that the effects of the INHs were on GS activity state because total GS activity was unaltered after either acute or chronic treatment. GS protein expression was also unchanged by chronic INH treatment (Fig. 6A).



View larger version (41K):
[in this window]
[in a new window]
  		FIG. 6. Influence of chronic INH treatment on GSK-3, GS, GLUT1, and GLUT4 protein expression. A: Representative Western blot image of GSK-3 and GS protein in muscle cells untreated or treated with 0.5, 1, or 2 µmol/l CHIR 98023 for 4 days in fusion media. Western blotting was performed as described in RESEARCH DESIGN AND METHODS. B: Quantitation of GSK-3{alpha} and GSK-3ß protein in muscle cells after chronic treatment with 2 µmol/l CHIR 98023, 2 µmol/l inactive compound (IA), or 20 mmol/l LiCl. Results are averages ± SE (n = 10; six nondiabetic patients, four diabetic patients). C: Representative Western blot image of GLUT1 and GLUT4 protein in muscle cells untreated or treated with 2 µmol/l CHIR 98023 or IA, or LiCl (20 mmol/l) for 4 days in fusion media. *P < 0.05 vs. untreated control or cells treated with IA or LiCl.

 
The sustained (2- to 4-day) increase in glucose uptake could not be explained by an upregulation of glucose transporters because INH treatment had no effect (Fig. 6C; 100 ± 14% of control, n = 4) on total cell GLUT1 protein expression. In keeping with the lack of effect of chronic exposure on glucose uptake, neither the inactive analog (101 ± 2%) nor LiCl (87 ± 4%) influenced GLUT1 content. A similar lack of change was seen for total cellular GLUT4 protein expression (Fig. 6C) after either INH (96 ± 10% of control, n = 4) or inactive analog (98 ± 2%) treatment.

Because prolonged INH treatment increased insulin action on glucose uptake (Fig. 4B) independent of changes in glucose transporter expression (Fig. 6C), the influence of INH treatment on the expression of several key insulin-signaling proteins was investigated. Chronic treatment of muscle cells caused a concentration-dependent increase in IRS-1 protein expression (Fig. 7A). There was an ~3.5-fold upregulation of IRS-1 protein after treatment with 2 µmol/l CHIR 98023 (P < 0.05, n = 10). Neither the inactive compound nor LiCl had any effect on IRS-1 protein expression. Increases in IRS-1 protein were first seen after 6 h of INH treatment, increasing for 24 h (Fig. 7B) and sustained for 96 h (not shown). This time course is consistent with that seen for CHIR 98023 action on glucose uptake (Fig. 4A). Moreover, the INH effect on IRS-1 was specific because Akt 1/2 protein abundance was unaltered by treatment (Fig. 7A). The consequences of IRS-1 upregulation on insulin signaling were investigated at the level of insulin stimulation of phosphorylation of Akt on serine 473, an event downstream of IRS-1 and PI 3-kinase (7,8). Stimulation of Akt phosphorylation at a maximal insulin level was unaltered by chronic treatment with either INHs or IA (Fig. 7C): 105 ± 15 and 98 ± 5% of the paired control response with INH and IA treatment, respectively (n = 4).



View larger version (57K):
[in this window]
[in a new window]
  		FIG. 7. Influence of chronic INH treatment on IRS-1 and Akt protein expression and Akt phosphorylation. A: Representative Western blot image of IRS-1 and Akt protein in muscle cells treated as described in the legend to Fig. 5. B: Time course of CHIR 98023 (2 µmol/l) effect on IRS-1 protein expression. Representative Western blot. C: Serine 473 phosphorylation of Akt in response to acute insulin exposure after chronic treatment of cells as described in Fig. 5.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
One approach to elucidating the importance of GSK-3 in insulin action and control of glucose metabolism has been the use of LiCl as an inhibitor of GSK-3. To better understand the role of GSK-3 in regulation of glucose metabolism, we used both LiCl and more selective and potent inhibitors of GSK-3. CHIR 98014 and CHIR 98023 have 500- to 10,000-fold selectivity for GSK-3 over a large number of tested kinases (26). For example, CHIR 98014 has a Ki of ~10 nmol/l for GSK-3 (both isoforms with similar potency) and stimulates GS with an IC50 of 50–100 nmol/l (26), orders of magnitude more selective than LiCl (17,34). In addition, both INHs (CHIR 98014 and CHIR 98023) appear to have higher affinities and better selectivity than several recently described GSK-3 inhibitors (35). Besides stimulating GS, these compounds, collectively referred to here as INHs, can augment insulin action on glucose uptake into skeletal muscle from insulin-resistant Zucker diabetic fatty rats (36). The experimental system used in the current study is cultured human skeletal muscle cells, which maintain many of the metabolic properties of skeletal muscle, including impaired GS activity in cells from diabetic subjects (24,25).

As would be expected, INHs acutely activated GS in human muscle cells at concentrations far lower than LiCl. Other GSK-3 inhibitors have also been demonstrated to increase glycogen synthesis in liver cells (35). The currently studied INHs alone were more effective than either insulin or LiCl. INHs were able to augment insulin action on GS, whether added together with or after insulin. The increase in the response to a submaximal insulin dose might indicate the ability of INHs to improve insulin sensitivity. The maximal phosphorylation and deactivation attainable in response to insulin is not enough to fully inactivate GSK-3, whereas INHs can directly and more completely block enzyme activity.

Prolonged treatment of muscle cells with INHs was tested as a model more closely resembling the therapeutic situation. In the overall time course of INH action on GS, we observed two phases: a rapid activation that was complete within a half hour and a gradual increase over 6–24 h that was sustained even longer. This was opposite to the response to insulin, with transient activation of GS and then development of desensitization, as has been reported by multiple investigators of other cell types (37). The prolonged upregulation of GS activity in response to INH treatment involves GS activation because total GS activity and protein expression were unaltered. The progressive GS activation apparently involves downregulation of GSK-3 protein expression because total activity and protein expression were reduced to the same extent. Protein abundance of both isoforms, which are present at similar amounts in control cells, was decreased in INH-treated cells. The downregulation of GSK-3 proteins appears to involve inhibition of the enzyme because the response was observed with INHs and not the inactive analog. The lack of effect of LiCl on GSK-3 expression may be related to reduced potency over extended times and/or selectivity relative to INHs. Control of GSK-3 expression appears to be a second mechanism, available to INHs and not Li, for regulation of GSK-3 activity.

Several laboratories have reported that GS protein expression is normal in the skeletal muscle of type 2 diabetic subjects (30,38). Together with the evidence that GSK-3 expression is elevated in skeletal muscle of type 2 diabetic subjects (25), this would suggest that an abnormally low GS/GSK-3 ratio is a feature of diabetic skeletal muscle, shifting the balance toward inactivation of GS. This behavior is also present in cultured muscle cells, where the ratio of GS protein to GSK-3 in cells from diabetic subjects (0.52 ± 0.08, n = 7) is significantly lower than the same value in nondiabetic cells (1.09 ± 0.12, n = 7, P < 0.005). Agents that can both inhibit and downregulate GSK-3 may have an added therapeutic benefit for downregulation of GSK-3, whereas not influencing GS expression would have the ultimate result of increasing the GS/GSK-3 ratio; such a change would drive GS and GSK-3 toward a more normal balance. The specific molecular mechanism(s) by which INHs downregulate GSK-3, impaired synthesis, and/or accelerated degradation are unknown and represent an intriguing area for further investigation.

Li has been shown in some (34, 39,40) but not all (41,15) situations to acutely stimulate glucose transport or GLUT4 translocation. This response differs from activation of GS because it can be blocked with wortmannin (34), indicating that it occurs at the level of PI 3-kinase activation, whereas GS stimulation is not wortmannin sensitive and occurs downstream of PI 3-kinase (34,15). Cultured human skeletal muscle cells behave much like other cells because Li is as effective as insulin in acutely stimulating glucose uptake. Whether the glucose transport response to Li involves direct inhibition of GSK-3 is uncertain because INHs have little acute effect. Other mechanisms for Li action on glucose transport have been proposed after ruling out inhibition of myo-inositol-1-monophosphatase and accumulation of inositol monophosphates (40). These mechanisms may include effects on Ca2+ and 1,6 bisphosphatase (19,41). In rat muscles, Li has been shown to change Ca2+ intracellular distribution, which could lead to activation of glucose transport (42). The lack of acute INH effect on glucose uptake in muscle cells is in agreement with studies in isolated muscles from ZDF rats (36), where uptake in the absence of insulin is unaltered by short-term exposure to CHIR 98014.

Insulin and Li have a similar activation profile on glucose uptake. These agents acutely stimulate glucose uptake followed by desensitization. In contrast, the INH effect on glucose uptake was delayed but caused a gradual and sustained increase. The increases in glucose uptake with INH treatment could not be attributed to changes in transporter protein expression, indicating that INHs may be acting on other aspects of transporter function, such as transporter intrinsic activity or localization to the plasma membrane; these questions remain to be studied. Unlike GS, where chronically activated enzymes in INH-treated cultures could not be stimulated further by insulin, glucose uptake could still be stimulated by insulin to a level approximately twofold greater than that possible in control cells. Although partly the result of an elevation of basal uptake, this final response suggests that insulin action may also be augmented.

The possibility that regulation of protein expression is one mechanism for the chronic effects of GSK-3 inhibitors is supported by the fact that GSK-3 phosphorylates and activates a number of transcription factors (43–45). GSK-3 is also a predominant kinase of translation initiation factor, eIF2B (46), phosphorylation of which causes its inactivation. Thus, inhibition of GSK-3 might reactivate protein synthesis at the level of translation. Alternatively, the upregulation of glucose uptake by INHs could be indirect—the result of a pull of intracellular glucose and glucose-6-phosphate into glycogen by activated GS.

There have been reports in which inhibition of GSK-3 has been shown to increase insulin action on glucose transport in isolated rodent skeletal muscles (26,41) and 3T3-L1 adipocytes (34,47). When seeking possible mechanisms for increased insulin action, we found that chronic INH treatment increases IRS-1 protein expression with a time course similar to that for INH effects on GS activity and glucose uptake. Such an upregulation of IRS-1 could potentiate insulin action, just as overexpression of IRS-1 has been shown to do in cell lines (48). The INH-induced upregulation of IRS-1 was not part of a generalized increase in insulin-signaling molecules because Akt expression was unaltered. IRS-1 has been identified as an in vivo substrate for GSK-3, and, acutely, GSK-3-mediated phosphorylation can impair its function (16). In addition, hyperphosphorylation of IRS-1 on serine residues induces IRS-1 degradation in proteosomes (49,50). Hence, inhibition and/or downregulation of GSK-3 could reduce IRS-1 phosphorylation and slow its degradation. Alternatively, IRS-1 protein synthesis could increase as a result of GSK-3 inhibition and reactivation of the translation initiation factor eIF2B (45). Whatever the mechanism, an increase in IRS-1 protein expression in skeletal muscle could augment insulin action, a further therapeutic benefit beyond activation of GS. This potential insulin-sensitizing action of GSK-3 inhibition might be even more obvious in vivo because we have recently demonstrated that muscle cells from type 2 diabetic subjects express normal amounts of IRS-1 protein (51), implicating something other than IRS-1 expression as the major site of impaired insulin signaling in vitro. Whatever the effects on insulin signaling, the INH-induced upregulation of IRS-1 expression was not found to increase insulin action on Akt phosphorylation. However, the current result was obtained at a maximally stimulating insulin concentration (33 nmol/l), which might obscure effects to improve insulin sensitivity.

The use of highly selective inhibitors has revealed several potential mechanisms by which GSK-3 can control glucose metabolism and insulin action in skeletal muscle. In the short term, GSK-3 acts to suppress GS activity and possibly reduce insulin sensitivity. In the long term, GSK-3 activity may provide a negative influence on glucose uptake and insulin signaling because inhibition of GSK-3 leads to upregulation of glucose uptake and insulin responsiveness. What is notable here is both the magnitude of upregulation with INHs and the delayed kinetics. In addition, GSK-3 activity appears to be required to sustain GSK-3 expression. Thus, along with expected effects on GS, GSK-3 can play roles in other more upstream events in insulin-signaling pathways. Sustained GSK-3 inhibition may represent a useful means of countering the reduced levels of muscle glucose uptake and metabolism characteristic in type 2 diabetes.

Whereas the current work has focused on the involvement of GSK-3 in glucose metabolism and insulin action, GSK-3 has been demonstrated to play a number of important roles, including control of cell differentiation and proliferation through the Wnt pathway (52) and regulation of specific gene transcription (53). Continuous activation of the Wnt pathway, associated with inhibition of GSK-3 activity, is often linked to tumor development (54). Additionally, a GSK-3ß knockout in mice is embryonically lethal because of liver degeneration (55). Thus, inhibition of GSK-3 has the potential for broad effects beyond metabolism. Yet Li has an extended history of therapeutic application, and augmented tumor formation has not been reported in those patients. In fact, evidence suggests that Li might even have a protective effect against cancer development (56). Considerable further study will be needed to sort out the various roles and regulation of GSK-3 in cell metabolism and development. Selective inhibitors of GSK-3 may prove to be useful tools in answering these questions.


   ACKNOWLEDGMENTS
 
This work was supported by grant Rd-DK-258291 from the National Institutes of Health; a grant from the Medical Research Service, Department of Veterans Affairs and VA San Diego Healthcare System; a grant from Chiron Corporation; and grant M01 RR-00827 in support of the General Clinical Research Center from the General Clinical Research Branch, Division of Research Sources, National Institutes of Health.


   FOOTNOTES
 
Address correspondence and reprint requests to R.R. Henry, MD, VA San Diego Health Care System (9111G), 3350 La Jolla Village Dr., San Diego, CA 92161. E-mail: rrhenry{at}vapop.ucsd.edu.

Received for publication 22 May 2001 and accepted in revised form 27 March 2002.

DTT, dithiothreitol; FV, fractional velocity; GS, glycogen synthase; GSK, glycogen synthase kinase; IA, inactive analog; INH, inhibitor; IRS, insulin receptor substrate; MEM, minimal essential medium; PI, phosphatidylinositol; PMSF, phenylmethylsulfonyl fluoride.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Embi N, Rylatt DB, Cohen P: Glycogen synthase kinase-3 from rabbit skeletal muscle: separation from cAMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 107:519–527, 1980[Medline]
  2. Hansen L, Arden KC, Rasmussen SB, Viars CS, Vestergaard H, Hansen T, Moller AM, Woodgett JR, Pedersen O: Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM. Diabetologia 40:940–946, 1997[Medline]
  3. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378:785–789, 1995[Medline]
  4. Ramakrishna S, Benjamin WB: Insulin action rapidly decreases multifunctional protein kinase activity in rat adipose tissue. J Biol Chem 263:12677–12681, 1988[Abstract/Free Full Text]
  5. Shaw M, Cohen P, Alessi DR: Further evidence that the inhibition of glycogen synthase kinase-3beta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 416:307–311, 1997[Medline]
  6. Welsh GI, Proud CG: Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 294:625–629, 199
  7. Moule SK, Welsh GI, Edgell NJ, Foulstone EJ, Proud CG, Denton RM: Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and beta-adrenergic agonists in rat epididymal fat cells: activation of protein kinase B by wortmannin-sensitive and -insensitive mechanisms. J Biol Chem 272:7713–7719, 1997[Abstract/Free Full Text]
  8. Cross DA, Watt PW, Shaw M, van der Kaay J, Downes CP, Holder JC, Cohen P: Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue. FEBS Lett 406:211–215, 1997[Medline]
  9. Halse R, Rochford JJ, McCormack JG, Vandenheede JR, Hemmings BA, Yeaman SJ: Control of glycogen synthesis in cultured human muscle cells. J Biol Chem 274:776–780, 1999[Abstract/Free Full Text]
  10. Parker PJ, Caudwell FB, Cohen P: Glycogen synthase from rabbit skeletal muscle: effect of insulin on the state of phosphorylation of the seven phosphoserine residues in vivo. Eur J Biochem 130:227–234, 1983[Medline]
  11. Roach PJ, Larner J: Covalent phosphorylation in the regulation of glycogen synthase activity. Mol Cell Biochem 15:179–199, 1997
  12. Lawrence JC Jr, Roach PJ: New insights into the role and mechanism of glycogen synthase activation by insulin. Diabetes 46:541–517, 1997[Abstract]
  13. Eldar-Finkelman H, Argast GM, Foord O, Fischer EH, Krebs EG: Expression and characterization of glycogen synthase kinase-3 mutants and their effect on glycogen synthase activity in intact cells. Proc Natl Acad Sci U S A 93:10228–10233, 1996[Abstract/Free Full Text]
  14. Skurat AV, Wang Y, Roach PJ: Rabbit skeletal muscle glycogen synthase expressed in COS cells: identification of regulatory phosphorylation sites. J Biol Chem 269:25534–22542, 1994[Abstract/Free Full Text]
  15. Summers SA, Kao AW, Kohn AD, Backus GS, Roth RA, Pessin JE, Birnbaum MJ: The role of glycogen synthase kinase 3 b in insulin-stimulated glucose metabolism. J Biol Chem 274:17934–17940, 1999[Abstract/Free Full Text]
  16. Eldar-Finkelman H, Krebs EG: Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci U S A 94:9660–9664, 1997[Abstract/Free Full Text]
  17. Stambolic V, Ruel L, Woodgett JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol 6:1664–1668, 1996[Medline]
  18. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 93:8455–8459, 1996[Abstract/Free Full Text]
  19. Bosh F, Rodriguez-Gil J, Hatzoglou M, Gomez-Foix A, Hanson R: Lithium inhibits hepatic gluconeogenesis and phosphoenolpyruvate carboxykinase gene expression. J Biol Chem 267:2888–2893, 1992[Abstract/Free Full Text]
  20. Rodriguez-Gil JE, Fernandez-Novell JM, Barbera A, Guinovart JJ: Lithium’s effects on rat liver glucose metabolism in vivo. Arch Biochem Biophys 375:377–384, 2000[Medline]
  21. Hers I, Tavare JM, Denton RM: The protein kinase C inhibitors bisindolymaleimide I (GF 109203x) and IX (Ro 31–8220) are potent inhibitors of glycogen synthase kinase-3 activity. FEBS Lett 460:433–436, 1999[Medline]
  22. Nikoulina SE, Ciaraldi TP, Mudaliar S, Mohideen P, Carter L, Henry RR: Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes. Diabetes 49:263–271, 2000[Abstract]
  23. Nikoulina SE, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Henry RR: Regulation of glycogen synthase activity in cultured skeletal muscle cells from subjects with type II diabetes: role of chronic hyperinsulinemia and hyperglycemia. Diabetes 46:1017–1024, 1997[Abstract]
  24. Henry RR, Abrams L, Nikoulina S, Ciaraldi TP: Insulin action and glucose metabolism in nondiabetic control and NIDDM subjects: comparison using human skeletal muscle cell cultures. Diabetes 44:936–946, 1995[Abstract]
  25. Henry RR, Ciaraldi TP, Abrams-Carter L, Mudaliar S, Park KS, Nikoulina SE: Glycogen synthase activity is reduced in cultured skeletal muscle cells of non-insulin-dependent diabetes mellitus subjects: biochemical and molecular mechanisms. J Clin Invest 98:1231–1236, 1996[Medline]
  26. Harrison SD, Nuss JM, Johnson KW,Goff D, Bloodworth LC, Dorr H, Shuling F, Ma ST, Reeder JW, Ring DB: Selective inhibitors of glycogen synthase kinase 3 with effects on insulin signaling (Abstract). Diabetes 49 (Suppl. 1):A328, 2000
  27. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997[Medline]
  28. Blau HM, Webster C: Isolation and characterization of human muscle cells. Proc Natl Acad Sci U S A 78:5623–5627, 1981[Abstract/Free Full Text]
  29. Sarabia V, Lam L, Burdett E, Leiter LA, Klip A: Glucose uptake in human and animal muscle cells in culture. Biochem Cell Biol 68:536–542, 1990[Medline]
  30. Thorburn AW, Gumbiner B, Bulacan F, Wallace P, Henry RR: Intracellular glucose oxidation and glycogen synthase activity are reduced in non-insulin-dependent (type II) diabetes independent of impaired glucose uptake. J Clin Invest 85:522–529, 1990[Medline]
  31. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254, 1976[Medline]
  32. Ciaraldi TP, Abrams L, Nikoulina S, Mudaliar S, Henry RR: Glucose transport in cultured human skeletal muscle cells: regulation by insulin and glucose in nondiabetic and non-insulin-dependent diabetes mellitus subjects. J Clin Invest 96:2820–2827, 1995[Medline]
  33. Burnette WN: "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein. Anal Biochem 112:195–203, 1981[Medline]
  34. Orena SJ, Torchia AJ, Garofalo RS: Inhibition of glycogen synthase kinase-3 (GSK3) stimulates glycogen synthase and glucose transport by distinct mechanisms in 3T3–L1 adipocytes. J Biol Chem 275:15765–15772, 2000[Abstract/Free Full Text]
  35. Coghlan M, Culbert A, Cross D, Corcoran SL, Yates JW, Pearce NJ, Rausch OL, Murphy GJ, Carter PS, Roxbee Cox L, Mills D, Brown MJ, Haigh D, Ward RW, Smith DG, Murray KJ, Reith AD, Holder JC: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem Biol 7:793–803, 2000[Medline]
  36. Henriksen EJ, Johnson KW, Ring DB, Fang S, Kinnick TR, Ma S, Okeefe MP, Slabiak T, Wernette-Hammond ME, Harrison SD: Glycogen synthase kinase-3 (GSK3) inhibitors potentiate glucose tolerance and muscle glycogen synthase activity and glucose uptake in the Zucker Diabetic Fatty (ZDF) rat (Abstract). Diabetes 50 (Suppl. 2):A279, 2001
  37. Sone H, Suzuki H, Takahashi A, Yamada N: Disease model: hyperinsulinemia and insulin resistance. Part A. Targeted disruption of insulin signaling or glucose transport. Trends Mol Med 7:320–322, 2001[Medline]
  38. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O: Glycogen synthase and phosfructokinase protein and mRNA levels in skeletal muscle from insulin-resistant patients with non-insulin-dependent diabetes mellitus. J Clin Invest 91:2342–2350, 1993[Medline]
  39. Furnsinn C, Noe C, Herdlicka R, Roden M, Nowotny P, Leighton B, Waldhausl W: More marked stimulation by lithium than insulin of the glycogenic pathway in rat skeletal muscle. Am J Physiol 273:E514–E520, 1997[Abstract/Free Full Text]
  40. Chen X, McMahon E, Gulve E: Stimulatory effect of lithium on glucose transport in rat adipocytes is not mediated by elevation of IP1. Am J Physiol 275:E272–E277, 1998[Abstract/Free Full Text]
  41. Tabata I, Schluter J, Gulve E, Holloszy J: Lithium increases susceptibility of muscle glucose transport to stimulation by various agents. Diabetes 43:903–907, 1994[Abstract]
  42. Bigornia L, Bihler I: The role of calcium in stimulation of sugar transport in muscle by lithium. Biochim Biophys Acta 816:197–207, 1985[Medline]
  43. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR: Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim Biophys Acta 1114:147–162, 1992[Medline]
  44. Woodgett JR: Regulation and functions of the glycogen synthase kinase-3 subfamily. Sem Cancer Biol 5:269–275, 1994[Medline]
  45. Welsh G, Wilson C, Proud C: GSK3: a SHAGGY frog story. Trends Cell Biol 6:274–279, 1996[Medline]
  46. Jefferson LS, Fabian JR, Kimbal SR: Glycogen synthase-3 is the predominant insulin-regulated eukariotic initiation factor 2B kinase in skeletal muscle. Intl J Biochem Cell Biol 31:191–200, 1999[Medline]
  47. Orena SJ, Torchia AJ, Garofalo RS: A role for glycogen synthase kinase-3 (GSK3) in the desensitization of insulin signaling to glycogen synthase in 3T3–L1 adipocytes (Abstract). Diabetes 49 (Suppl. 1):A244, 2000
  48. Wilden PA, Broadway DE: Effect of phosphotyrosyl-IRS-1 level and insulin receptor tyrosine kinase activity on insulin-stimulated phosphotyidylinositol 3, MAP and S6 kinase activities. J Cell Physiol 63:9–19, 1995
  49. Smith LK, Rice KM, Garner GM: The insulin-induced down-regulation of IRS-1 in 3T3–L1 adipocytes is mediated by a calcium-dependent thiol protease. Mol Cell Endocrinol 122:81–92, 1996[Medline]
  50. Sun XJ, Goldberg JL, Qiao L-Y, Mitchell JJ: Insulin-induced insulin receptor substrate-1 degradation is mediated by the proteosome degradation pathway. Diabetes 48:1359–1364, 1999[Abstract]
  51. Nikoulina SE, Ciaraldi TP, Larter L, Mudaliar S, Park KS, Henry RR: Impaired muscle glycogen synthase in type 2 diabetes is associated with diminished phosphatidylinositol 3-kinase activation. J Clin Endocrinol Metab 86:4307–4314, 2001[Abstract/Free Full Text]
  52. Kim L, Kimmel AR: GSK3, a master switch regulating cell-fate specification and tumorigenesis. Curr Opin Genet Dev 10:508–514, 2000[Medline]
  53. Ross SE, Erickson RL, Hemati N, MacDougald OA: Glycogen synthase kinase 3 is an insulin-regulated C/EBP{alpha} kinase. Mol Cell Biol 19:8433–8441, 1999[Abstract/Free Full Text]
  54. Morin PJ: Beta-catenin signaling and cancer. Bioessays 21:1021–1030, 1999[Medline]
  55. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR: requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature 406:86–90, 2000[Medline]
  56. Cohen Y, Chretrit A, Cohen Y, Sirota P, Modan B: Cancer morbidity in psychiatric patients: influence of lithium carbonate treatment. Med Oncol 15:32–36, 1998[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
A. Moh, W. Zhang, S. Yu, J. Wang, X. Xu, J. Li, and X.-Y. Fu
STAT3 Sensitizes Insulin Signaling by Negatively Regulating Glycogen Synthase Kinase-3{beta}
Diabetes, May 1, 2008; 57(5): 1227 - 1235.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. P. Ciaraldi, S. E. Nikoulina, R. A. Bandukwala, L. Carter, and R. R. Henry
Role of Glycogen Synthase Kinase-3{alpha} in Insulin Action in Cultured Human Skeletal Muscle Cells
Endocrinology, September 1, 2007; 148(9): 4393 - 4399.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
T. P. Ciaraldi, D. K. Oh, L. Christiansen, S. E. Nikoulina, A. P. S. Kong, S. Baxi, S. Mudaliar, and R. R. Henry
Tissue-specific expression and regulation of GSK-3 in human skeletal muscle and adipose tissue
Am J Physiol Endocrinol Metab, November 1, 2006; 291(5): E891 - E898.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. B. Dokken and E. J. Henriksen
Chronic selective glycogen synthase kinase-3 inhibition enhances glucose disposal and muscle insulin action in prediabetic obese Zucker rats
Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E207 - E213.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
O. Kaidanovich-Beilin and H. Eldar-Finkelman
Long-Term Treatment with Novel Glycogen Synthase Kinase-3 Inhibitor Improves Glucose Homeostasis in ob/ob Mice: Molecular Characterization in Liver and Muscle
J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 17 - 24.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
B. B. Dokken, J. A. Sloniger, and E. J. Henriksen
Acute selective glycogen synthase kinase-3 inhibition enhances insulin signaling in prediabetic insulin-resistant rat skeletal muscle
Am J Physiol Endocrinol Metab, June 1, 2005; 288(6): E1188 - E1194.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. MacAulay, A. S. Blair, E. Hajduch, T. Terashima, O. Baba, C. Sutherland, and H. S. Hundal